Biocartis Group Overview
- Year Founded
-
2007
- Status
-
Out of Business
- Employees
-
420
- Latest Deal Type
-
Liquidation
Biocartis Group General Information
Description
Developer of a molecular diagnostics platform designed to support cancer diagnosis and treatment decisions. The company's platform offers molecular diagnostic testing, oncology-focused biomarker analysis, and automated testing capabilities, enabling healthcare providers and clinical laboratories to improve diagnostic accuracy and support personalized cancer care.
Contact Information
Website
www.biocartisgroupnv.beCorporate Office
- Generaal De Wittelaan 11B
- 2800 Mechelen
- Belgium
Corporate Office
- Generaal De Wittelaan 11B
- 2800 Mechelen
- Belgium
Biocartis Group Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 18. Bankruptcy: Liquidation | 15-Dec-2025 | Completed | Bankruptcy: Liquidation | |||
| 17. PIPE | 29-Nov-2022 | Completed | Generating Revenue | |||
| 16. PIPE | 23-Jan-2019 | Completed | Generating Revenue | |||
| 15. Debt - General | 28-Feb-2018 | Completed | Generating Revenue | |||
| 14. PIPE | 28-Nov-2017 | Completed | Generating Revenue | |||
| 13. PIPE | 01-Jun-2017 | Completed | Generating Revenue | |||
| 12. PIPE | 17-Nov-2016 | Completed | Generating Revenue | |||
| 11. IPO | 27-Apr-2015 | Completed | Generating Revenue | |||
| 10. Accelerator/Incubator | $337M | Completed | Generating Revenue | |||
| 9. Later Stage VC | 04-Sep-2014 | $85.5M | $337M | Completed | Generating Revenue |
Biocartis Group Comparisons
Industry
Financing
Details
Biocartis Group Competitors (32)
One of Biocartis Group’s 32 competitors is PixCell Medical Technologies, a Formerly VC-backed company based in Yokneam Ilit, Israel.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| PixCell Medical Technologies | Formerly VC-backed | Yokneam Ilit, Israel | ||||
| MDxHealth | Formerly VC-backed | Liège, Belgium | ||||
| Mindera Health | Venture Capital-Backed | Vista, CA | ||||
| BioFire | Venture Capital-Backed | Salt Lake City, UT | ||||
| Hain Lifescience | Corporate Backed or Acquired | Nehren, Germany |
Biocartis Group Patents
Biocartis Group Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024240872-A1 | Cartridges comprising tablets | Inactive | 23-May-2023 | ||
| EP-4701784-A1 | Semi-solid phase extraction of nucleic acids using a quaternary salt and cation mixture in alkaline conditions | Pending | 26-Apr-2023 | ||
| US-20260297555-A1 | Semi-solid phase extraction of nucleic acids using a quaternary salt and cation mixture in alkaline conditions | Pending | 26-Apr-2023 | ||
| WO-2024223814-A1 | Semi-solid phase extraction of nucleic acids using a quaternary salt and cation mixture in alkaline conditions | Inactive | 26-Apr-2023 | ||
| AU-2021367997-A1 | Generic cartridge and method for multiplex nucleic acid detection | Pending | 29-Oct-2020 | C12Q1/6823 |
Biocartis Group Signals
Biocartis Group Investments & Acquisitions (5)
Biocartis Group’s most recent deal was a Later Stage VC with Asylia Diagnostics for . The deal was made on 18-Feb-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Asylia Diagnostics | 18-Feb-2025 | Later Stage VC | Discovery Tools (Healthcare) | ||
| Molecular Diagnostics (Biocartis / Wondfo) | 03-Sep-2018 | Joint Venture | Diagnostic Equipment | ||
| Pronota | 04-Sep-2014 | Merger/Acquisition | Diagnostic Equipment | ||
| Royal Philips Electronics (Technology Platform) | 10-Feb-2010 | Merger/Acquisition | Diagnostic Equipment | ||
| Memobead Technologies | Merger/Acquisition | Discovery Tools (Healthcare) |
Biocartis Group ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
29.87 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Healthcare
Industry
of 590
Rank
Percentile
Medical Devices
Subindustry
of 209
Rank
Percentile
Biocartis Group FAQs
-
When was Biocartis Group founded?
Biocartis Group was founded in 2007.
-
Where is Biocartis Group headquartered?
Biocartis Group is headquartered in Mechelen, Belgium.
-
What is the size of Biocartis Group?
Biocartis Group has 420 total employees.
-
What industry is Biocartis Group in?
Biocartis Group’s primary industry is Diagnostic Equipment.
-
Is Biocartis Group a private or public company?
Biocartis Group is a Private company.
-
What is Biocartis Group’s current revenue?
The current revenue for Biocartis Group is .
-
How much funding has Biocartis Group raised over time?
Biocartis Group has raised $749M.
-
Who are Biocartis Group’s competitors?
PixCell Medical Technologies, MDxHealth, Mindera Health, BioFire, and Hain Lifescience are some of the 32 competitors of Biocartis Group.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process